, Volume 64, Issue 7, pp 649-650

Disodium ascorbyl phytostanol phosphate. A new cholesterol-lowering drug?

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access
This is an excerpt from the content

The Adult Treatment Panel III (ATP III) Guidelines [1] have revised the treatment goals for the reduction of low-density lipoprotein (LDL)-cholesterol in patients. For those patients at a moderate to high risk, the target goal is a LDL-cholesterol level of <2.6 mmol/L (= <100 mg/dL); for those at a very high risk, the target goal is <1.8 mmol/L  (= <70 mg/dL) The most potent cholesterol drugs in current use are the statins [2], but not all patients using these drugs are reaching the ATP III goal. Therefore, new cholesterol-lowering compounds are necessary in addition to the statins so that more patients will achieve their target/treatment goal. It is beleived that an increased number of patients would be able to approach the ATP III goal if ezetimibe were to be added to ongoing statin therapy [3]. Ezetimibe is a drug which diminishes intestinal cholesterol absorption [4]. However, the recent study published by the leading author of the present article (ref. Nr. 6 old, 7 new) (Kastelein